Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus
dc.contributor.author | Somers, Emily C. | en_US |
dc.contributor.author | Marder, Wendy | en_US |
dc.contributor.author | Christman, Gregory M. | en_US |
dc.contributor.author | Ognenovski, Vladimir | en_US |
dc.contributor.author | McCune, William Joseph | en_US |
dc.date.accessioned | 2006-09-20T15:01:07Z | |
dc.date.available | 2006-09-20T15:01:07Z | |
dc.date.issued | 2005-09 | en_US |
dc.identifier.citation | Somers, Emily C.; Marder, Wendy; Christman, Gregory M.; Ognenovski, Vladimir; McCune, W. Joseph (2005)."Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus." Arthritis & Rheumatism 52(9): 2761-2767. <http://hdl.handle.net/2027.42/48676> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/48676 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16142702&dopt=citation | en_US |
dc.description.abstract | Objective Cyclophosphamide (CYC) therapy for systemic lupus erythematosus (SLE), a disease predominantly affecting women of childbearing age, causes an unacceptably high incidence of irreversible premature ovarian failure (POF). This study was performed to evaluate the effectiveness of depot leuprolide acetate, a synthetic gonadotropin-releasing hormone analog (GnRH-a), for protection against POF during CYC therapy. Methods Young women with severe SLE treated in a standardized protocol of monthly intravenous bolus CYC were offered treatment with GnRH-a (depot leuprolide acetate; a 3.75-mg monthly injection during the standard CYC regimen). Patients treated with GnRH-a were compared with controls individually matched by age (±5 years) and by cumulative CYC dose (±5 gm). Reproductive status was determined after a minimum followup of 3 years after CYC therapy. The primary outcome was time to POF. Paired summary statistical analyses, Kaplan-Meier survival estimates, and Cox regression analyses were performed to assess differences in outcome between groups. Results POF developed in 1 of 20 women treated with GnRH-a (5%) compared with 6 of 20 controls (30%) matched by age and cumulative CYC dose (matched odds ratio 0.09, P < 0.05). Kaplan-Meier estimates demonstrated improved cumulative ovarian protection over time in the GnRH-a–treated group ( P = 0.04). Conclusion Treatment with GnRH-a during CYC therapy was associated with a significant reduction of POF in young women with severe SLE. | en_US |
dc.format.extent | 78457 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Health System, Ann Arbor and London School of Hygiene and Tropical Medicine, London, UK | en_US |
dc.contributor.affiliationum | University of Michigan Health System, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan Health System, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan Health System, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan Health System, Ann Arbor ; 3918 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0358 | en_US |
dc.identifier.pmid | 16142702 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/48676/1/21263_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/art.21263 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.